Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer.
Guo X, Nie H, Zhang W, Li J, Ge J, Xie B, Hu W, Zhu Y, Zhong N, Zhang X, Zhao X, Wang X, Sun Q, Wei K, Chen X, Ni L, Zhang T, Lu S, Zhang L, Dong C.
Guo X, et al. Among authors: hu w.
Cancer Cell. 2025 Jan 28:S1535-6108(25)00019-4. doi: 10.1016/j.ccell.2025.01.001. Online ahead of print.
Cancer Cell. 2025.
PMID: 39889705